These insights not only advance our comprehension of the KLF4/Lnc18q22.2/ULBP3 axis's influence on hypoxia‐induced HCC tumorigenesis, particularly regarding immune evasion, but also underscore the potential of this axis as a therapeutic target. The gene discussed is KLF4; the disease is hepatocellular carcinoma.